top of page
Untitled (1500 × 400 px).png

2022 Conference Speakers

Associate Professor of Radiology, University of Chicago

Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.

In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.


Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.

Surgical Oncologist, College of WI

Dr. Callisia N. Clarke completed her medical degree at the University of Cincinnati College of Medicine where she was elected to the Alpha Omega Alpha Honors Society. She completed a general surgery residency at the University of Cincinnati Medical Center in Cincinnati, Ohio in 2013 and a fellowship in Complex General Surgical Oncology at The University of Texas MD Anderson Cancer Center in 2016. She joined the faculty at the Medical College of Wisconsin in 2016 as an Assistant Professor of Surgery in the Division of Surgical Oncology.

Dr. Clarke specializes in hepato-pancreatic-biliary malignancies, melanoma and sarcoma, with her research efforts centered epigenetic regulation of Neuroendocrine Tumors. She holds numerous leadership positions in national organizations including the American Hepato Pancreato-Biliary Association, the Association for Academic Surgery, the North American Neuroendocrine Tumor Society, and the Society of Surgical Oncology.

Associate scientist, Sunnybrook Health Sciences Centre

Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist at the Odette Cancer Centre - Sunnybrook Health Sciences Centre specialized in hepato-biliary, pancreatic and upper gastrointestinal malignancies, with a clinical focus on minimally invasive therapies, as well as neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. 

She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology fellowship in the hepato-pancreatio-biliary tract program at the University of Toronto, and additional training in advanced minimally invasive and robotic hepato-pancreatico-biliary surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France.

As a surgeon investigator, her research focuses on health services research to examine processes, patterns of care, and outcomes of hepato-pancreato-biliary malignancies and neuroendocrine tumors, with a focus on patient engagement and patient-reported/patient-centered outcomes. Her research is supported by operating grants from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research, as well as prior early career investigator awards from the Society of Surgery of the Alimentary Tract and the North American Neuroendocrine Tumors Society.

Medical Oncologist, Cedars-Sinai Medical Center

The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program.

Radiologist, UCSF

Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is also the Associate Chair for Joint Ventures for Radiology. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine, and he completed a one year internship at Kaiser Permanente, San Francisco.

From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013. Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He led the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors at UCSF.

Medical Oncologist, Mercy Medical

Sandy D. Kotiah, M.D., a Board-Certified medical oncologist, serves as the Director of The Neuroendocrine Tumor Center at Mercy and is a member of Medical Oncology and Hematology at Mercy in Baltimore, Maryland. Dr. Kotiah leads a multidisciplinary team of specialty doctors focused on providing some of the best treatment options for rare neuroendocrine diseases. Dr. Kotiah’s compassionate and caring nature as well as her exceptional clinical knowledge and dedication to searching for answers to complicated cancer diagnoses makes her a sought-after Medical Oncologist and Hematologist in the Baltimore region.

Dr. Sandy Kotiah, who is fluent in both French and Creole, has been recognized with a “Patients' Choice Award.” The award is presented on behalf of patient feedback and in recognition of Dr. Kotiah’s compassionate care and bedside manner. She also has been named a "Top Doctor" in Medical Oncology by Baltimore magazine, as well as Castle Connolly Medical, Ltd.

Medical Oncologist, City of Hope

Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics.

Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018.

1 N0zyuwwg_Beh0PB_-hEJmA.jpeg
President, NorCal CarciNET

Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, acting COO the World Association of Radiopharmaceutical and Molecular Therapy (WARMTH), and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States.

In addition, he is a member of National Cancer Institute’s GI Steering Committee after being a member of the NCI Task Force on Neuroendocrine Tumors for seven years. Josh is also a member of the Board of Directors and Executive Committee of the Neuroendocrine Tumor Research Foundation(NETRF). He sits as the single patient member of NETRF's Scientific Advisory Committee which reviews research applications for private funding by this 501c3 foundation. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO)and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures.

Medical Oncologist, Memorial Sloan Kettering

Dr. Reidy-Lagunes is a medical oncologist who cares for people with gastrointestinal and endocrine cancers, including neuroendocrine, adrenal, colon, appendix, and pancreatic cancers, and cholangiocarcinoma. She joined Memorial Sloan Kettering in 2008 and works as part of a team of experts who have chosen to dedicate their passion, knowledge, and experience to caring for people affected by these cancers. Her research is focused on finding methods to use a molecular-based approach to treat neuroendocrine and adrenocortical cancers. 

Medical Oncologist, Fox Cancer Center

Coming from a family of 12 doctors, Dr. Vijayvergia wanted to be one for as long as she can remember. After graduating from medical school in India, she pursued Internal Medicine training at Temple University Hospital in Philadelphia, where she also served as a chief medical resident. During that time Dr. Vijayvergia became interested in oncology and clinical research. She recently completed my fellowship in hematology/oncology at Temple/Fox Chase Cancer Center and have been fortunate enough to stay on as faculty. Early in her training, she realized that she wanted to dedicate her career to help discover new therapies for patients with gastrointestinal cancers, with a particular focus on pancreatic and neuroendocrine malignancies. 

bottom of page